Starna Therapeutics Valuation, Funding & Investors

Biocytogen is a biotechnology company offering end-to-end antibody discovery platforms using gene-edited RenMab mice and B-cell screening. Its services span humanized animal model creation, hybridoma sequencing, and bispecific antibody engineering for oncology and immunology targets. Headquartered in Beijing with US facilities in Wakefield, Massachusetts, Biocytogen partners with over 100 global pharmas including Takeda and Novartis, delivering candidates like fully human antibodies validated in cynomolgus models.

Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.

Vanqua Bio is a Cambridge, Massachusetts-headquartered biotech firm developing therapies for neurodegenerative diseases like Parkinson's and ALS using a platform that screens human genetics and patient-derived neurons targeting lysosomal storage disorders and innate immune activation pathways.

Dewpoint Therapeutics is a Boston, Massachusetts-headquartered biotechnology company founded in 2018 modulating biomolecular condensates for diseases like ALS and cancer. The Condensate Dialysis platform screens compounds disrupting pathological condensates using AI-driven imaging, with lead candidates targeting FUS protein aggregates entering Phase 1 trials in 2023.

Readline is a Shenzhen-headquartered biopharmaceutical firm pioneering enzyme-directed evolution for green manufacturing of active pharmaceutical ingredients. Specializing in peptides, carbohydrates, and nucleic acids, it supplies intermediates for medicines, cosmetics, animal feed, and biological pesticides, emphasizing sustainable production processes at industrial scale.

Inceptive is a biotechnology firm that engineers RNA molecules through deep learning models refined by high-throughput wet-lab experiments. Headquartered in South San Francisco, the company builds platforms for designing mRNA vaccines, gene therapies, and protein therapeutics. Its Evo 2.0 model generates novel RNA sequences with specified properties, accelerating development of treatments for infectious diseases and rare genetic disorders.

Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.

Cellarity is a Cambridge, Massachusetts-headquartered AI drug discovery company. The company maps cellular states via single-cell RNA sequencing and machine learning for fibrosis and metabolic diseases. Cellarity raised $250 million in 2023 and advances two programs to preclinical. Founded in 2017, it collaborates with Biogen.

FogPharma is a Cambridge, Massachusetts-headquartered biopharmaceutical company developing cell-penetrating mini-proteins for oncology targets. The platform addresses previously undruggable proteins in solid tumors through proprietary Helicon technology advancing toward clinical candidates.

Zhejiang Shouxiangu Pharmaceutical Co Ltd is a Chinese pharmaceutical company.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Apnimed is a Cambridge-based clinical-stage biopharma company founded in 2017 developing pharmacologic therapies for obstructive sleep apnea. Its lead candidate targets upper airway muscle activity to address the condition affecting over 20 million Americans. Apnimed advances oral treatments as alternatives to CPAP devices.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Cuorips is a biopharmaceutical company founded in 2017 and based in Japan. Cuorips conducts research and development of regenerative medicine products, such as iPS cells, and optimization of manufacturing and quality processes and supply systems. Cuorips supports physician-initiated clinical trials of iPS cell-derived cardiomyocyte sheets conducted by Osaka University. The company serves business and institutional customers through products and services in the biopharmaceutical market. Its commercial model is built primarily on technology licensing and product sales, reflecting the way customers obtain and use its offering. JIC Venture Growth Investments classifies the business in its After Market portfolio and records March 2021 and September 2026 for the company. The company maintains its operating website at www.cuorips.co.jp, while JIC VGI's portfolio materials preserve the public record of the investment relationship.

Fosun Kite Biotechnology is a Shanghai-based joint venture between Fosun Pharmaceutical and Kite Pharma established in 2019. It develops CAR-T cell therapies targeting hematologic malignancies like lymphoma and leukemia. The company manufactures Yescarta and Tecartus generics for the Chinese market and conducts clinical trials at sites in Shanghai and Suzhou. Fosun Kite holds NMPA approvals for domestic distribution.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.